You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 15, 2025

Litigation Details for Parkervision, Inc. v. Qualcomm Incorporated (M.D. Fla. 2011)


✉ Email this page to a colleague

« Back to Dashboard


Biologic Drugs cited in Parkervision, Inc. v. Qualcomm Incorporated

The biologic drugs covered by the patents cited in this case are ⤷  Try for Free , ⤷  Try for Free , ⤷  Try for Free , and ⤷  Try for Free .

Parkervision, Inc. v. Qualcomm Incorporated: A Comprehensive Litigation Summary and Analysis

Background of the Litigation

The litigation between Parkervision, Inc. and Qualcomm Incorporated began in July 2011, when Parkervision filed a patent infringement lawsuit against Qualcomm in the U.S. District Court for the Middle District of Florida (Case No. 3:11-cv-00719)[5].

Patents in Dispute

Parkervision alleged that Qualcomm had infringed several of its patents related to the technology of down-converting electromagnetic signals using "energy sampling." The patents in question included U.S. Patents 6,061,551, 6,266,518, 7,496,342, and 6,370,371[2].

Initial Trial and Jury Verdict

Phase 1: Validity and Infringement

The district court bifurcated the trial into two phases. The first phase addressed the issues of patent validity and infringement. At the conclusion of this phase, the jury returned a verdict in October 2013, rejecting Qualcomm's invalidity claims and finding that Qualcomm had directly and indirectly infringed multiple claims across four patents[2].

Phase 2: Damages and Willfulness

The second phase of the trial dealt with damages and willfulness. The jury awarded Parkervision $172.7 million in damages but found that Qualcomm's infringement was not willful[2].

Post-Trial Motions and Appeals

Judgment as a Matter of Law (JMOL)

Following the jury verdict, Qualcomm filed a motion for judgment as a matter of law (JMOL) of non-infringement, which the district court granted in part but denied the motions relating to invalidity. Both parties appealed this decision, and the Federal Circuit affirmed the district court's decision in what is known as "ParkerVision I"[1][5].

Second Infringement Suit and IPR Challenges

New Patents and Claims

In 2014, Parkervision filed a second infringement suit against Qualcomm, involving different but related patents. This action included patents with claims related to down-conversion ("receiver claims") and up-conversion ("transmitter claims")[1].

Inter Partes Review (IPR) Challenges

Qualcomm filed IPR challenges to the validity of Parkervision's patents, which led to significant delays in the litigation process. The district court later granted Qualcomm's motion for summary judgment of non-infringement based on collateral estoppel from the first lawsuit (ParkerVision I)[1].

Federal Circuit Appeal and Rulings

Issues on Appeal

Parkervision raised three key issues on appeal:

  1. Collateral Estoppel: Whether the district court properly granted summary judgment of non-infringement based on collateral estoppel from ParkerVision I.
  2. Expert Testimony: Whether the district court correctly applied collateral estoppel to prevent Parkervision's validity expert's testimony.
  3. Exclusion of Expert Testimony: Whether the district court properly excluded Parkervision's infringement experts' testimony as unreliable[1].

Federal Circuit's Decision

The Federal Circuit agreed with Parkervision on all three issues:

Collateral Estoppel

The Federal Circuit vacated the district court's summary judgment of non-infringement. It found that the district court erred in its collateral estoppel analysis by not conducting claim construction or analyzing intrinsic evidence. Instead, the district court relied on extrinsic evidence, particularly Qualcomm's expert reports, which was deemed incorrect. The court emphasized that Qualcomm, as the party invoking collateral estoppel, bore the burden of proving the identity of the issues, and the district court's approach was flawed[1][5].

Expert Testimony

The Federal Circuit reversed the district court's exclusion of Parkervision's validity expert. It clarified that findings from IPR proceedings do not collaterally estop patentees from arguing the validity of separate but related claims in district court litigation. Qualcomm needed to prove invalidity by clear and convincing evidence in district court, a burden it had not yet met[1][4].

Exclusion of Infringement Experts' Testimony

The Federal Circuit found that the district court erred in requiring testing and simulation for expert testimony reliability. It highlighted that expert opinions can be based on schematics and technical documents, which are standard in the field, and that the district court should have allowed the jury to evaluate the experts' opinions[1][5].

Key Takeaways

  • Collateral Estoppel: The Federal Circuit emphasized the importance of proper claim construction and analysis of intrinsic evidence in determining collateral estoppel.
  • Evidentiary Burdens: The court clarified that IPR findings do not collaterally estop patentees from arguing validity in district court, as the burden of proof differs significantly between IPR and district court proceedings.
  • Expert Testimony: The court reinforced that expert opinions can be reliable based on standard technical documents and schematics, without the need for testing and simulation.

FAQs

What was the initial lawsuit about?

The initial lawsuit filed by Parkervision in 2011 alleged that Qualcomm had infringed several of Parkervision's patents related to down-converting electromagnetic signals using "energy sampling."

What was the outcome of the first trial?

The jury found that Qualcomm had directly and indirectly infringed multiple claims across four patents and awarded Parkervision $172.7 million in damages.

What were the key issues on appeal in the second lawsuit?

The key issues included whether the district court properly applied collateral estoppel, whether the district court correctly excluded Parkervision's validity expert's testimony, and whether the district court properly excluded Parkervision's infringement experts' testimony.

How did the Federal Circuit rule on the appeal?

The Federal Circuit vacated the summary judgment of non-infringement, reversed the exclusion of Parkervision's expert testimonies, and remanded the case for further proceedings.

What is the significance of the Federal Circuit's ruling on collateral estoppel?

The ruling emphasized that collateral estoppel requires a thorough analysis of claim construction and intrinsic evidence, and that findings from IPR proceedings do not automatically apply to district court litigation.

Sources

  1. JDSupra: "Different Evidentiary Burdens in IPR Proceedings and District Court Litigation"[1]
  2. Casetext: "Parkervision, Inc. v. Qualcomm Inc., 621 F. App'x 1009"[2]
  3. Justia: "Parkervision, Inc. v. Qualcomm Incorporated, No. 3:2011cv00719"[3]
  4. IPWatchdog: "CAFC Vacates Summary Judgment Ruling in Third ParkerVision Appeal, Finds Improper Collateral Estoppel Analysis"[4]
  5. RPX Insight: "Federal Circuit Unwinds Noninfringement Rulings That Ended ParkerVision Case"[5]

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.